GlassScriptPhysician profile
Chad Barnett
NPI 1912103615
$2,020.82
in general payments reported to CMS, 2019-2025
34 companies · $1,659 in 2025
The $1,659 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $53.15 · 2023: $67.05 · 2024: $242 · 2025: $1,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,967.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $343.43 | 2024-2025 | |
| Tersera Therapeutics LLC | $235.17 | 2024-2025 | Quzyttir |
| Corcept Therapeutics | $143.95 | 2024-2025 | Korlym |
| Lilly USA, LLC | $128.22 | 2025 | Mounjaro, Kisunla, Zepbound |
| Amgen INC. | $91.77 | 2024-2025 | Repatha, Otezla, Evenity |
| Tris Pharma INC | $91.32 | 2024-2025 | Dyanavel Xr |
| Csl Behring | $90.05 | 2025 | Hizentra, Andembry |
| Astrazeneca Pharmaceuticals LP | $80.61 | 2024-2025 | Airsupra, Farxiga |
| Lundbeck LLC | $79.36 | 2024-2025 | Vyepti |
| Abbott Laboratories | $74.13 | 2022-2025 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.97 | 2025 | Caplyta |
| Medtronic, INC. | $55.27 | 2024-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $53.47 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Phathom Pharmaceuticals, INC. | $42.22 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $37.38 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.47 | 2025 | Jardiance, Ofev |
| Pfizer INC. | $32.57 | 2025 | |
| Azurity Pharmaceuticals, INC. | $30.54 | 2024-2025 | Edarbyclor, Horizant |
| Biocryst US Sales Co., LLC | $25.98 | 2025 | Orladeyo |
| Novo Nordisk INC | $25.94 | 2025 | Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $23.51 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Dexcom, INC. | $22.61 | 2023 | Dexcom G6 Transmitter |
| Organon LLC | $21.90 | 2025 | Nexplanon |
| Ascendis Pharma Endocrinology INC | $20.49 | 2023 | |
| Corium, LLC | $20.27 | 2024-2025 | Azstarys |
| Gilead Sciences, INC. | $19.33 | 2025 | |
| Cranial Technologies, INC | $18.84 | 2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $17.13 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $16.26 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $16.08 | 2024 | Cuvitru |
| Kowa Pharmaceuticals America, INC. | $15.69 | 2025 | Zoryve |
| Eton Pharmaceuticals, INC. | $13.27 | 2023 | Alkindi |
| Dynavax Technologies Corporation | $12.94 | 2025 | Heplisav-B |
| Beta Bionics, INC. | $10.68 | 2023 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Barnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.